MARGARITA BAKA

Dr. MARGARITA BAKA


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
EVEleni Vasileiou
Eleni Vasileiou
APAnna Paisiou
Anna Paisiou
CTCharoula Tsipou
Charoula Tsipou
APAPOSTOLOS POURTSIDIS
APOSTOLOS POURTSIDIS
VGVasiliki Galani
Vasiliki Galani
ATHANASIOS TRAGIANNIDISATHANASIOS TRAGIANNIDIS
ATHANASIOS TRAGIANNIDIS
Candidemia is an important cause of morbidity and mortality especially in immunocompromised and hospitalized patients. We retrospectively collected data of candidemia cases that occurred in the seven Hematology-Oncology Departments/Units of Greece and the Stem Cell Transplant Unit between 2015 and 2019. In total, 19 episodes of candidemia in 19 patients were recorded. The majority of the patients (78.9%) had at least one risk factor for candidemia. The most frequent risk factors associated with candidemia observed in our patients were prolonged duration of hospitalization (30 days, range 1–141), presence of a central venous catheter at diagnosis of candidemia (73.7%) and antibiotics use during the last two weeks (84.2%). Candida parapsilosis was the most common species isolated accounting for 42.1%, followed by C. albicans (26.3%) and C. famata (15.8%). Nearly all of the patients (84.2%) received antifungal monotherapy with liposomal amphotericin B or echinocandins. The central venous catheter was removed in 78.6% of patients and the median time between the first positive blood culture and catheter removal was 3 days (range 1–9). Mortality at 28 days was 26.3%. In conclusion, a predominance of non-albicans species was observed in our study in conformity with the global trend.

1 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MXMarieta Xagorari
Marieta Xagorari
AMAntonios Marmarinos
Antonios Marmarinos
LKLydia Kossiva
Lydia Kossiva
MBMARGARITA BAKA
MARGARITA BAKA
DDDimitrios Doganis
Dimitrios Doganis
DGDimitrios Gourgiotis
Dimitrios Gourgiotis
Glucocorticoids (GCs) remain the cornerstone of childhood acute lymphoblastic leukemia (chALL) therapy, exerting their cytotoxic effects through binding and activating of the glucocorticoid receptor (GR). GAS5 lncRNA acts as a potent riborepressor of GR transcriptional activity, and thus targeting GAS5 in GC-treated chALL could provide further insights into GC resistance and support personalized treatment decisions. Herein, to study the clinical utility of GAS5 in chALL prognosis and chemotherapy response, GAS5 expression was quantified by RT-qPCR in bone marrow samples of chB-ALL patients at diagnosis (n = 164) and at end-of-induction (n = 109), treated with ALL-BFM protocol. Patients’ relapse and death were used as clinical end-points for survival analysis. Bootstrap analysis was performed for internal validation, and decision curve analysis assessed the clinical net benefit for chALL prognosis. Our findings demonstrated the elevated GAS5 levels in blasts of chALL patients compared to controls and the significantly higher risk for short-term relapse and poor treatment outcome of patients overexpressing GAS5, independently of their clinicopathological data. The unfavorable prognostic value of GAS5 overexpression was strongly validated in the high-risk/stem-cell transplantation subgroup. Finally, multivariate models incorporating GAS5 levels resulted in superior risk stratification and clinical benefit for chALL prognostication, supporting personalized prognosis and precision medicine decisions in chALL.

21 October 2023 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
KNKleanthis Nizamis
Kleanthis Nizamis
VKVassilios Kalliakmanis
Vassilios Kalliakmanis
NKNikos Koutsoupias
Nikos Koutsoupias
SPSophia Polychronopoulou
Sophia Polychronopoulou
MBMARGARITA BAKA
MARGARITA BAKA
EHEMMANOUEL HATZIPANTELIS
EMMANOUEL HATZIPANTELIS
Cancer as a whole, but especially childhood cancer, creates a number of psychological, social, and family problems as well as practical and financial issues, which every parent is called upon to solve. This study focuses on childhood cancer and aims at a thorough analysis of the physical/organic, psychological, and social problems associated with the parents and relatives of a child with cancer. The special element in pediatric neoplasms is not only the vulnerable population target group, but also the set of secondary effects it has on the environment of the sick child. The research was conducted on a sample of 133 families of children with cancer, and the results were displayed after statistical processing and data analysis with R statistical software. The results of the study confirm with statistically significant data the effect of childhood cancer on the physical, mental, and social health and behavior of the parent. Thus, 53.8% of the respondents stated 5 and above on the 7-point Likert scale for fatigue issues, 55.6% for sleep disorders, 78.1% for stress, and 82.7% for fear. The key findings are characterized by high specificity as it is a unique study that reveals particular aspects of the Greek parent’s behavior, mind, and body during the period of their child’s illness. Conclusion: The effects of childhood illnesses, particularly when they are severe, such as neoplasms, present a looming threat, ushering in a multitude of adverse alterations in the daily lives of the affected child's family. What is Known – What is New:• We know the effects that a childhood illness brings not only to the sick child, but also to the entire family circle. The new element in the present research is that these data reflect the situation in Greece, for which the research data in this area is quite limited. Our research is one of the few studies that demonstrate with statistical data the change in the psychosomatic health of the parent who has a child with cancer.

10 January 2022 in Cancer Epidemiology
Verified
Journal Article
Closed access
MKMaria A Karalexi
Maria A Karalexi
AKAndreas Katsimpris
Andreas Katsimpris
PPParaskevi Panagopoulou
Paraskevi Panagopoulou
PBPanagiota Bouka
Panagiota Bouka
JSJoachim Schüz
Joachim Schüz
EBEvdoxia Bouka
Evdoxia Bouka

24 October 2013 in memo - Magazine of European Medical Oncology
Verified
Journal Article
Closed access
PDF file
SPSophia Polychronopoulou
Sophia Polychronopoulou
MBMARGARITA BAKA
MARGARITA BAKA
MSMarina Servitzoglou
Marina Servitzoglou
VPVassilios Papadakis
Vassilios Papadakis
APApostolos Pourtsidis
Apostolos Pourtsidis
HKHelen Kosmidis
Helen Kosmidis

1 February 2021 in Cancer Epidemiology
Verified
Journal Article
Closed access
MKMary Karalexi
Mary Karalexi
MSMarina Servitzoglou
Marina Servitzoglou
Maria MoschoviMaria Moschovi
Maria Moschovi
RMRoman Moiseenko
Roman Moiseenko
PBPanagiota Bouka
Panagiota Bouka
SVSvetlana Varfolomeeva
Svetlana Varfolomeeva